International Journal of Radiation Oncology * Biology * Physics
Volume 51, Issue 3 , Pages 614-623 , 1 November 2001

A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy

  • W.Robert Lee, M.D., M.S.

      Affiliations

    • Comprehensive Cancer Center of Wake Forest University School of Medicine, Winston-Salem, NC, USA
    • Corresponding Author InformationReprint requests to: W. Robert Lee, M.D., Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1030. Tel: 336-716-4630; Fax: 336-716-7837
    • ,
  • M.Craig Hall, M.D.

      Affiliations

    • Comprehensive Cancer Center of Wake Forest University School of Medicine, Winston-Salem, NC, USA
    • ,
  • Richard P McQuellon, Ph.D.

      Affiliations

    • Comprehensive Cancer Center of Wake Forest University School of Medicine, Winston-Salem, NC, USA
    • ,
  • L.Douglas Case, Ph.D.

      Affiliations

    • Comprehensive Cancer Center of Wake Forest University School of Medicine, Winston-Salem, NC, USA
    • ,
  • David L McCullough, M.D.

      Affiliations

    • Comprehensive Cancer Center of Wake Forest University School of Medicine, Winston-Salem, NC, USA

Received 20 February 2001 ,Revised 5 May 2001 ,Accepted 4 June 2001.

References 

  1. Stewart AL, Hays RD, Ware JEJ. The MOS short-form general health survey, Reliability and validity in a patient population. Med Care. 1988;26:724–735
  2. Kaasa S. Measurement of quality of life in clinical trials. Oncology. 1992;49:289–294
  3. Greenlee RT, Murray T, Bolden S, et al.  Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33
  4. Millikan R, Logothetis C. Update of the NCCN Guidelines for treatment of prostate cancer. Oncology. 1997;11:180–193
  5. Arterbery VE, Frazier A, Dalmia P, et al.  Quality of life after permanent prostate implant. Semin Surg Oncol. 1997;13:461–464
  6. Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy (Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30). Qual Life Res. 1996;5:212–222
  7. Borghede G, Karlsson J, Sullivan M. Quality of life in patients with prostatic cancer (Results from a Swedish population study). J Urol. 1997;158:1477–1486
  8. Brandeis JM, Litwin MS, Burnison CM, et al.  Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol. 2000;163:851–857
  9. Clark JA, Rieker P, Propert KJ, et al.  Changes in quality of life following treatment for early prostate cancer. Urology. 1999;53:161–168
  10. Esper P, Mo F, Chodak G, et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–928
  11. Joly F, Brune D, Couette JE, et al.  Health-related quality of life, and sequelae in patients treated with brachytherapy, and external beam irradiation for localized prostate cancer. Ann Oncol. 1998;9:751–757
  12. Krongrad A, Granville LJ, Burke MA, et al.  Predictors of general quality of life in patients with benign prostate hyperplasia or prostate cancer. J Urol. 1997;157:534–538
  13. Krongrad A, Litwin MS, Lai H, et al.  Dimensions of quality of life in prostate cancer. J Urol. 1998;160:807–810
  14. Lee WR, McQuellon RP, Case LD, et al.  Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol. 1999;162:403–406
  15. Lee WR, McQuellon RP, Harris-Henderson K, et al.  A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;46:77–81
  16. Litwin MS, Hays RD, Fink A, et al.  Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:129–135
  17. Litwin MS, Hays RD, Fink A, et al.  The UCLA Prostate Cancer Index (Development, reliability, and validity of a health-related quality of life measure). Med Care. 1998;36:1002–1012
  18. Litwin MS, McGuigan KA, Shpall AI, et al.  Recovery of health related quality of life in the year after radical prostatectomy (Early experience). J Urol. 1999;161:515–519
  19. Lubeck DP, Litwin MS, Henning JM, et al.  Measurement of health-related quality of life in men with prostate cancer (the CaPSURE database). Qual Life Res. 1997;6:385–392
  20. Lubeck DP, Litwin MS, Henning JM, et al.  Changes in health-related quality of life in the first year after treatment for prostate cancer (results from CaPSURE). Urology. 1999;53:180–186
  21. Shrader-Bogen CL, Kjellberg JL, McPherson CP, et al.  Quality of life and treatment outcomes (Prostate carcinoma patients’ perspectives after prostatectomy or radiation therapy). Cancer. 1997;79:1977–1986
  22. Talcott JA, Rieker P, Clark JA, et al.  Patient-reported symptoms after primary therapy for early prostate cancer (Results of a prospective cohort study). J Clin Oncol. 1998;16:275–283
  23. Litwin MS. Health related quality of life in older men without prostate cancer. J Urol. 1999;161:1180–1184
  24. Barry MJ, Fowler FJJ, O’Leary MP, et al.  Measurement Committee of the American Urological Association   The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 1992;148:1549–1557
  25. Cella DF, Tulsky DS, Gray G, et al.  The Functional Assessment of Cancer Therapy Scale (Development and validation of the general measure). J Clin Oncol. 1993;11:570–579
  26. Beahrs OH, Henson DE, Hutter RVP  American Joint Committee on Cancer . Manual for staging of cancer. 4th ed.. Philadelphia: JB Lippincott; 1992;
  27. Blasko JC, Ragde H, Luse RW, et al.  Should brachytherapy be considered a therapeutic option in localized prostate cancer?. Urol Clin North Am. 1996;23:633–650
  28. Grimm PD, Blasko JC, Ragde H, et al.  Does brachytherapy have a role in the treatment of prostate cancer. Hematol Oncol Clin North Am. 1996;10:653–673
  29. Bice WS, Prestidge BR, Prete JJ, et al.  Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using I-125. Int J Radiat Oncol Biol Phys. 1998;40:1237–1241
  30. Sloan JA, O’Fallon JR, Suman VJ, et al. Incorporating quality of life measurement in oncology clinical trials. Proc Biometrics Sect Am Stat Assoc 1997:282–287.
  31. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms (A comparison of two techniques). J Clin Epidemiol. 1996;49:1215–1219
  32. Ringash J, O’Sullivan B, Bezjak A, et al.  Minimal important difference for quality of life measures in about five to ten percent of the instrument range. Am Soc Clin Oncol Proc. 2000;19:434a
  33. Wells GA, Tugwell P, Kraag GR, et al.  Minimum important difference between patients with rheumatoid arthritis (The patient’s perspective). J Rheumatol. 1993;20:557–560

PII: S0360-3016(01)01707-2

doi: 10.1016/S0360-3016(01)01707-2

International Journal of Radiation Oncology * Biology * Physics
Volume 51, Issue 3 , Pages 614-623 , 1 November 2001

Article Tools

* Image Usage & Resolution